List view / Grid view
An open letter has underscored the challenges of return failure in the US drug supply chain, especially after the introduction of the Drug Supply Chain Security Act in November.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
The US supply of heparin, an ingredient used in anticoagulant drugs and found in pigs, is under threat due to an outbreak of disease in Chinese herds.
The two Canadian provinces have expressed concern over the new draft regulations, claiming that the reforms would delay patient access to medicines.
The Middle Eastern country has a limited supply of vital medication needed for conditions such as cancer due to US trade blocks.
In another bid to lower medication prices in the US, Donald Trump has announced a draft plan to import drugs from Canada.
The pharmaceutical industry is set to face some major changes in the near future, to improve the quality of returned drugs and medications.
Teva Pharmaceuticals, Endo Pharmaceuticals and Teikoku will pay almost $70 million to the US state for delaying drugs to keep prices high.
The successful pilot programme could represent an important step forward in biopharmaceutical supply chain innovation.
Altaire Pharmaceuticals has announced a recall of 31 products due to a lack of sterility assurance from their manufacturing facility.
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
Pharmaceutical packaging in China has increased at a rate of 10 percent in recent years and is predicted to continue high growth.
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
Three API re-packers who failed to meet current good manufacturing practice requirements have received warning letters from the FDA.
